Reason for posting: Rosuvastatin (Crestor) is a relatively new cholesterol-lowering drug that
has become one of the top-selling new pharmaceuticals since it was first marketed in …

We applaud the work of Ronaldson et al.[1] in evaluating the prevalence of risk factors in the
setting of rhabdomyolysis. As a minor point, they note that more patients experiencing …

We read with great interest the study of Chang et al. on rhabdomyolysis and statins. 1 When
our group studied the Food and Drug Administration's Adverse Event Reporting System …

Objective: To assess the frequency of risk factors for rhabdomyolysis with simvastatin and
atorvastatin in cases reported to the Australian Adverse Drug Reactions Advisory Committee …

Bayer's abrupt worldwide withdrawal of Baycol (cerivastatin) in August 2001 came as a
surprise given that rhabdomyolysis is a side effect common to all statins. 1, 2 We questioned …

Rhabdomyolysis is a well-documented side effect of statin therapy. This risk is increased
with concurrent use of medications that inhibit cytochrome p450-3A4 (CYP3A4), such as …

Rhabdomyolysis is a rare but life-threatening complication of statin therapy. A 74-year-old
man, treated with atorvastatin, developed rhabdomyolysis after the co-administration of …

Background Statins have a well-established role in prevention of vascular events but are
associated with muscle-related adverse events. The dose relationship with these adverse …

Cholesterol-lowering statins are frequently prescribed for primary and secondary prevention
of ischaemic vascular events. Whereas most patients tolerate statins without problems, statin …

Background Rhabdomyolysis is a rare but serious side effect of lipid-lowering therapy. In
response to the high rhabdomyolysis frequency, cerivastatin is no longer available in the …